FindTrial
Sign In

New"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease" trial

New"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease" trial - New "COOPERATE" trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002448
Enrollment
150
Registered
2009-09-07
Start date
2009-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-diabetic renal diseases

Interventions

ACE-I alone ARB alone Combination of ACE-I and ARB

Sponsors

Showa University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)non-diabetic CKD patients with a written informed consent

Exclusion criteria

Exclusion criteria: 1)hemodialysis or peritoneal dialysis patients 2)patients with remarkable edema 3)patients who need therapy with steroid and/or immunosuppresants 4)alcohol abuse 6)expecting mothers 7)those allergic to ACE-I or ARB

Design outcomes

Primary

MeasureTime frame
time to doubling of serum creatinine concentration or ESRD—

Secondary

MeasureTime frame
blood pressure, proteinuria—

Countries

Japan

Contacts

Public ContactHiroyuki Morita

Showa University Fujigaoka Hospital Division of Nephrology, Department of Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026